Hypertension management in diabetic patients: Prescribing trends from 1999 to 2005 in three Japanese university hospitals

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 9, 2008, Pages 904-911

  Kamijima, Yukari ^a   Ooba, Nobuhiro ^a   Yagame, Mitsunori ^b   Samizo, Kazuo ^c   Shimodozono, Yoshihiro ^d   Kageyama, Shigeru ^e   Horiguchi, Shingo ^a   Nagai, Ryozo ^a   Kusunoki, Tadashi ^f   Kubota, Kiyoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c Bohsei Pharmacy   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Japanese Society for Pharmacoepidemiology   (Japan)

Author keywords

Antihypertensive agents; Antihypertensive therapy; Cross sectional studies; Diabetes mellitus; Drug therapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG UTILIZATION; FEMALE; HEALTH INSURANCE; HUMAN; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; TREND STUDY;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DISEASE MANAGEMENT; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; PRESCRIPTIONS;

EID: 52949142351     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1609     Document Type: Article

References (42)

1. Akazawa Y. Prevalence and incidence of diabetes mellitus by WHO criteria. Diabetes Res Clin Pract 1994; 24 (Suppl): S23-S27.
2. Diabetes Drafting Group, Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetologia 1985; 28: 615-640.
3. Kuzuya T, Akanuma Y, Akazawa Y, Uehata T. Prevalence of chronic complications in Japanese diabetic patients. Diabetes Res Clin Pract 1994; 24 (Supp)): S159-S164.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977-986. DOI: 10.1056/ NEJM199309303291401
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-853. DOI: 10.1016/ S0140-6736(98)07019-6
6. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 (Suppl 2): B21-B29.
7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317(7160): 703-713.
8. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002; 25(1): 134-147. DOI: 10.2337/diacare.25.1.134
9. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension; principal results of the hyperotension optimal treatment (HOT) randomised trial. Lancet 1998; 351(9118): 1755-1762. DOI: 10.1016/S0140-6736 (98)04311-6
10. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25 (Suppl 1): S71-S73. DOI: 10.2337/diacare.25.2007.S71
11. Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension 2000; 36(4): 600-603.
12. Lopez J, Meier J, Cunningham F, Siegel D. Antihypertensive medication use in the Department of Veterans Affairs: a national analysis of prescribing patterns from 2000 to 2002. Am J Hypertens 2004; 17: 1095-1099, DOI: 10.1016/j.amjhyper.2004.07.015
13. Hicks LS, Fairchild DO, Horng MS, Orav EJ, Bates DW, Ayanian JZ. Determinants of JNC VI Guideline adherence, intensity of drug therapy, and blood pressure control by race and ethnicity. Hypertension 2004; 44(4): 429-434. DOI: 10.1161/01.HYP.0000141439.34834.84
14. Tu K, Campbell NRC, Duong-Hua M, McAlister FA. Hypertension management in the elderly has improved: Ontario prescribing trends, 1994 to 2002. Hypertension 2005; 45(6): 1113-1118. DOI: 10.1161/ 01.HYP.0000164573.01177.95
15. Campbell NRC, Tu K, Brant R, Duong-Hua M, McAlister FA. The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends. Hypertension 2006; 47(1): 22-28. DOI: 10.1161/01.HYP.0000196269.98463.fd
16. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26 (Suppl 1): S80-S82, DOI: 10.2337/diacare.26.2007.S80
17. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 2004; 27 (Suppl 1): S65-S67. DOI: 10.2337/diacare.27.2007.S65
18. Parving HH, Lehnert H, Bröchner-Monensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345(12): 870-878. DOI: 10.1056/NEJMoa011489
19. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoproctective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851-860. DOI: 10.1056/NEJMoa011303
20. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861-869. DOI: 10. 1056/NEJMoa011161
21. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276(23): 1886-1892. DOI: 10.1001/jama.276.23.1886
22. Nielsen F S, Rossing P, Gall MA, Skott P, Smidt UM. Parving HH. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46(7): 1182-1188. DOI: 10.2337/diabetes.46.7.1182
23. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing the risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317(7160): 713-720.
24. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension. Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613-634. DOI: 10.1291/hypres.24.613
25. Ramsay LE, Yeo WW, Jackson PR. Influence of diuretics, calcium antagonists, and alpha-blockers on insulin sensitivity and glucose tolerance in hypertensive patients. J Cardiovasc Pharmacol 1992; 20 (Suppl 11): S49-S54.
26. Ramsay LE, Yeo WW, Jackson PR. Diabetes impaired glucose tolerance and insulin resistance with diuretics. Eur Heart J 1992; 13 (Suppl G): 68-71.
27. Weinberger MH. Mechanisms of diuretic effects on carbohydrate tolerance, insulin sensitivity and lipid levels. Eur Heart J 1992; 13 (Suppl G): 5-9.
28. Harper R, Ennis CN, Heaney AP, et al. A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995; 38: 853-859. DOI: 10.1007/s001250050363
29. Prince MJ, Stuart CA, Padia M, Bandi Z, Holland OB. Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient. Enalapril for hypertensive diabetics. Arch Intern Med 1988; 148: 2363-2368. DOI: 10.1001/archinte.148.11.2363
30. Clausen-Sjobom N, Lins PE, Adamson U, Curstedt T, Hamberger B. Effects of metoprolol on the counter-regulation and recognition of prolonged hypoglycemia in insulin-dependent diabetics. Acta Med Scand 1987; 222: 57-63.
31. Guidelines Subcommittee of Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004. Life-science: Tokyo, 2004 (in Japanese).
32. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997. DOI: 10.1001/jama.288.23.2981
33. Campbell JC, Ikegami N. The Art of Balance in Health Policy: Maintaining Japan's Low-Cost Egalitarian System. Cambridge University Press: Cambridge, 1998.
34. Ohyama Y, Funao K, Kawabe E, et al. Calcium channel blockers and myocardial infarction: a case-control study in a Japanese hospital. Pharmacoepidemiol Drug Saf 2002; 11: 487-492. DOI: 10.1002/ pds.743
35. Shimazaki T, Kadoaki T, Ohyama Y, Ohe K, Kubota K. HbA1c predicts future drug treatment for diabetes mellitus: a follow-up study using routine clinical data in a Japanese university hospital. Transl Res 2007; 149(4): 196-204. DOI: 10.1016/j.trsl.2006.09.008
36. Anonymous. Yakuji Handbook 2000. Jiho: Tokyo, 2000 (in Japanese).
37. Anonymous. Yakuji Handbook 2006. Jiho: Tokyo, 2006 (in Japanese).
38. Mori H, Ukai H, Yamamoto H, et al. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143-151. DOI: 10.1291/ hypres.29.143
39. Hirose H, Saito I. Trends in blood pressure control in hypertensive patients with diabetes mellitus in Japan. Hypertens Res 2003; 26: 717-722. DOI: 10.1291/hypres.26.717
40. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 169S-173S. DOI: 10.1378/chest.129.1_suppl.169S
41. Sone H, Yoshimura Y, Ito H, Ohashi Y, Yamada N. Energy intake and obesity in Japanese patients with type 2 diabetes. Lancet 2004; 363(9404): 248-249. DOI: 10.1016/S0140-6736(03)15348-2
42. Eeley EA, Stratton IM, Hadden DR, Turner RC, Holman RR. UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. Diabet Med 1996; 13: 656-.662. DOI: 10.1002/(SICI)1096.-9136(199607)13:7< 656::AID-DIA131>3.0.CO;2-5